Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Total Liabilities (2021 - 2025)

Kezar Life Sciences' Total Liabilities history spans 5 years, with the latest figure at $14.8 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 50.89% year-over-year to $14.8 million; the TTM value through Sep 2025 reached $14.8 million, down 50.89%, while the annual FY2024 figure was $27.8 million, 17.52% down from the prior year.
  • Total Liabilities for Q3 2025 was $14.8 million at Kezar Life Sciences, up from -$91.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $33.7 million in Q4 2023 and bottomed at -$91.8 million in Q2 2025.
  • The 5-year median for Total Liabilities is $22.2 million (2025), against an average of $17.7 million.
  • The largest annual shift saw Total Liabilities surged 105.78% in 2022 before it plummeted 413.95% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $21.1 million in 2021, then soared by 41.03% to $29.7 million in 2022, then rose by 13.37% to $33.7 million in 2023, then decreased by 17.52% to $27.8 million in 2024, then tumbled by 46.88% to $14.8 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Total Liabilities are $14.8 million (Q3 2025), -$91.8 million (Q2 2025), and $22.2 million (Q1 2025).